Ortho Evra (Evra)

Subscribe to Selected New Research on Ortho Evra

7 relevant articles (0 outcomes, 3 trials/studies) found for this Drug

Description: a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6 mg norelgestromin and 0.75 mg ethinyl estradiol; was indexed to norelgestromin (2002-2006)

Also Known As:

Evra; norelgestromin-ethinyl estradiol combination patch

Drug Context: Research Results

Polycyclic Compounds: 58

Ethinyl Estradiol: 626

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 44075

Gonadal Hormones: 245

Gonadal Steroid Hormones: 2145

Estradiol Congeners: 104

Alkylated Estrogenic Steroids

Ethinyl Estradiol: 626

Ortho Evra: 7

Experts

1.	Hedon, Bernard: 1 article (02/2002)
2.	Fisher, Alan C: 1 article (02/2002)
3.	Shangold, Gary A: 1 article (02/2002)
4.	Zacur, Howard A: 1 article (02/2002)
5.	Mansour, Diana: 1 article (02/2002)
6.	Creasy, George W: 1 article (02/2002)

Related Diseases

1.	Weight Gain 04/01/2005 - "Eleven girls (39%) discontinued Ortho Evra (three lost health insurance, three because of application site reactions, two found patch application schedule difficult to remember, two desired pregnancy, two because of nausea, one because of perceived weight gain)" 01/01/2008 - "BACKGROUND: As weight gain is one of the most frequently cited reasons for not using and for discontinuing hormonal contraceptives, in an open-label, single-arm, multicentre clinical study we evaluated the effect of the ethinylestradiol/norelgestromin contraceptive patch (EVRA, Janssen-Cilag International, Belgium) on body composition using bioelectrical impedance analysis (BIA)" Get all the results and reference details, order at left...
2.	Adhesions 02/01/2002 - "Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions." 12/01/2001 - "The objectives of this randomized, open-label, three-period, incomplete block design study were to evaluate the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE) delivered by the contraceptive patch, Ortho Evra/Evra, and to evaluate patch adhesion under conditions of heat, humidity, and exercise" Get all the results and reference details, order at left...
3.	Stroke (Strokes) 02/01/2007 - "CONCLUSION: Ischemic stroke and acute myocardial infarction are rare among young women who use hormonal contraceptives, and the current data provide no suggestion of an increased risk of either ischemic stroke or acute myocardial infarction in users of the Ortho EVRA contraceptive patch compared with users of norgestimate OCs." 02/01/2007 - "STUDY OBJECTIVE: To compare rates of stroke and acute myocardial infarction in users of the Ortho EVRA contraceptive patch with these rates in users of norgestimate-containing oral contraceptives (OCs) with 35 microg of ethinyl estradiol" Get all the results and reference details, order at left...
4.	Myocardial Infarction 02/01/2007 - "CONCLUSION: Ischemic stroke and acute myocardial infarction are rare among young women who use hormonal contraceptives, and the current data provide no suggestion of an increased risk of either ischemic stroke or acute myocardial infarction in users of the Ortho EVRA contraceptive patch compared with users of norgestimate OCs." 02/01/2007 - "STUDY OBJECTIVE: To compare rates of stroke and acute myocardial infarction in users of the Ortho EVRA contraceptive patch with these rates in users of norgestimate-containing oral contraceptives (OCs) with 35 microg of ethinyl estradiol" Get all the results and reference details, order at left...
5.	Headache (Headaches) 04/01/2005 - "About a third (29%) of those with a history of recurrent headaches at initiation reported decrease in headaches, and about a third (33%) of those with acne at initiation reported decrease in facial acne while on Ortho Evra" 06/01/2005 - "A randomized clinical trial was conducted with 239 women at nine clinical research sites to compare bleeding profile, headache frequency, and subject satisfaction with the transdermal contraceptive, ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) used in an extended regimen (84 days) with a traditional, 28-day cyclic regimen" Get all the results and reference details, order at left...
10 Diseases and 7 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ortho Evra (Evra)
2.	Ethinyl Estradiol (Estinyl)
3.	norelgestromin
4.	Contraceptive Agents (Contraceptives)
5.	Oral Contraceptives
6.	norgestimate
6 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>